Predictors of Anticoagulation Control on Warfarin Therapy
NCT00905177 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 687
Last updated 2016-05-20
Summary
The goal of this research study is to develop better dosing of anticoagulation medication in both Caucasian and African Americans through analysis of various genetic factors.
Conditions
- Atrial Fibrillation
- Deep Vein Thrombosis
- Heart Valve Replacement
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH - lead OTHER
Principal Investigators
-
Stephen E. Kimmel, M.D. MS · University of Pennsylvania
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2013-08-31
- Completion
- 2013-08-31
Countries
- United States
Study Locations
More Related Trials
-
Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)
NCT00634907 ·Status: COMPLETED ·Phase: NA
-
Genetic Response to Warfarin in Healthy Subjects
NCT01520402 ·Status: COMPLETED ·Phase: NA
-
Early Identification of Warfarin Maintenance Dosage
NCT01178034 ·Status: COMPLETED ·Phase: PHASE3
-
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
NCT00365950 ·Status: COMPLETED ·Phase: PHASE4
-
Genotype-Guided Warfarin Therapy Trial
NCT00904293 ·Status: COMPLETED ·Phase: NA
-
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
NCT00247702 ·Status: UNKNOWN ·Phase: NA
-
Pharmacogenetics of Warfarin Induction and Inhibition
NCT01447511 ·Status: COMPLETED ·Phase: NA
-
Warfarin - How Good Are we at Maintaining Target Range ?
NCT01081327 ·Status: COMPLETED
-
Protocol for Improvement of Therapy With Warfarin
NCT06789588 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial
NCT00654823 ·Status: UNKNOWN
-
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
NCT01305148 ·Status: SUSPENDED ·Phase: NA
-
Safer Warfarin Treatment
NCT01042067 ·Status: SUSPENDED
-
Testing Strategies to Improving Warfarin Adherence
NCT00622102 ·Status: COMPLETED ·Phase: NA
-
Pharmacogenetic Dosing of Warfarin
NCT02065388 ·Status: COMPLETED ·Phase: PHASE3
-
Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling
NCT01964794 ·Status: COMPLETED
-
Pharmacogenetics of Warfarin in Puerto Ricans.
NCT01318057 ·Status: COMPLETED
-
Clinical and Economic Implications of Genetic Testing for Warfarin Management
NCT00964353 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
NCT02526485 ·Status: COMPLETED
-
Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin
NCT00927862 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin
NCT01119300 ·Status: COMPLETED ·Phase: PHASE4
-
Following Patients on Warfarin Therapy to See if Differences in Hemorrhagic Complications Exist
NCT00075985 ·Status: COMPLETED
-
Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
NCT01006733 ·Status: COMPLETED ·Phase: PHASE3
-
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage
NCT02061748 ·Status: COMPLETED
-
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
NCT06292117 ·Status: RECRUITING
-
Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity
NCT02069132 ·Status: UNKNOWN